PMC:6640909 / 81823-82603 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-122-129-7626","span":{"begin":251,"end":254},"obj":"[\"28365175\"]"},{"id":"31100109-233-240-7627","span":{"begin":369,"end":372},"obj":"[\"30184070\"]"},{"id":"31100109-113-120-7628","span":{"begin":679,"end":682},"obj":"[\"28365175\"]"},{"id":"31100109-122-129-7629","span":{"begin":688,"end":691},"obj":"[\"28125462\"]"},{"id":"31100109-81-88-7630","span":{"begin":775,"end":778},"obj":"[\"26720740\"]"}],"text":"The success rate of bridging children with MCS to a transplant or recovery using pulsatile or CF devices has improved with time. In the latest PEDIMACS report, an 84% 6-month survival rate on devices was reported with a transplant rate of nearly 50% [275], whereas the first Paedi-EUROMACS report shows a 6-month survival of 81% and a transplant rate of more than 50% [276]. Paediatric data on intracorporeal devices from EUROMACS demonstrated an on-device survival rate of 89% at 12 months [277]. Originally, the MCS devices used were mainly paracorporeal devices. More recently, an increase in the use of CF-LVAD in paediatric patients and patients with CHD has been reported [275, 278–281]. The obvious advantage is the ability to discharge these young patients home [282–286]."}

{"project":"MyTest","denotations":[{"id":"31100109-28365175-28905686","span":{"begin":251,"end":254},"obj":"28365175"},{"id":"31100109-30184070-28905687","span":{"begin":369,"end":372},"obj":"30184070"},{"id":"31100109-28365175-28905688","span":{"begin":679,"end":682},"obj":"28365175"},{"id":"31100109-28125462-28905689","span":{"begin":688,"end":691},"obj":"28125462"},{"id":"31100109-26720740-28905690","span":{"begin":775,"end":778},"obj":"26720740"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"The success rate of bridging children with MCS to a transplant or recovery using pulsatile or CF devices has improved with time. In the latest PEDIMACS report, an 84% 6-month survival rate on devices was reported with a transplant rate of nearly 50% [275], whereas the first Paedi-EUROMACS report shows a 6-month survival of 81% and a transplant rate of more than 50% [276]. Paediatric data on intracorporeal devices from EUROMACS demonstrated an on-device survival rate of 89% at 12 months [277]. Originally, the MCS devices used were mainly paracorporeal devices. More recently, an increase in the use of CF-LVAD in paediatric patients and patients with CHD has been reported [275, 278–281]. The obvious advantage is the ability to discharge these young patients home [282–286]."}

{"project":"0_colil","denotations":[{"id":"31100109-28365175-7626","span":{"begin":251,"end":254},"obj":"28365175"},{"id":"31100109-30184070-7627","span":{"begin":369,"end":372},"obj":"30184070"},{"id":"31100109-28365175-7628","span":{"begin":679,"end":682},"obj":"28365175"},{"id":"31100109-28125462-7629","span":{"begin":688,"end":691},"obj":"28125462"},{"id":"31100109-26720740-7630","span":{"begin":775,"end":778},"obj":"26720740"}],"text":"The success rate of bridging children with MCS to a transplant or recovery using pulsatile or CF devices has improved with time. In the latest PEDIMACS report, an 84% 6-month survival rate on devices was reported with a transplant rate of nearly 50% [275], whereas the first Paedi-EUROMACS report shows a 6-month survival of 81% and a transplant rate of more than 50% [276]. Paediatric data on intracorporeal devices from EUROMACS demonstrated an on-device survival rate of 89% at 12 months [277]. Originally, the MCS devices used were mainly paracorporeal devices. More recently, an increase in the use of CF-LVAD in paediatric patients and patients with CHD has been reported [275, 278–281]. The obvious advantage is the ability to discharge these young patients home [282–286]."}

{"project":"2_test","denotations":[{"id":"31100109-28365175-28905686","span":{"begin":251,"end":254},"obj":"28365175"},{"id":"31100109-30184070-28905687","span":{"begin":369,"end":372},"obj":"30184070"},{"id":"31100109-28365175-28905688","span":{"begin":679,"end":682},"obj":"28365175"},{"id":"31100109-28125462-28905689","span":{"begin":688,"end":691},"obj":"28125462"},{"id":"31100109-26720740-28905690","span":{"begin":775,"end":778},"obj":"26720740"}],"text":"The success rate of bridging children with MCS to a transplant or recovery using pulsatile or CF devices has improved with time. In the latest PEDIMACS report, an 84% 6-month survival rate on devices was reported with a transplant rate of nearly 50% [275], whereas the first Paedi-EUROMACS report shows a 6-month survival of 81% and a transplant rate of more than 50% [276]. Paediatric data on intracorporeal devices from EUROMACS demonstrated an on-device survival rate of 89% at 12 months [277]. Originally, the MCS devices used were mainly paracorporeal devices. More recently, an increase in the use of CF-LVAD in paediatric patients and patients with CHD has been reported [275, 278–281]. The obvious advantage is the ability to discharge these young patients home [282–286]."}